Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

CRANBURY, N.J., Sept. 22, 2011 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN), a biopharmaceutical company developing bremelanotide for sexual dysfunction indications and PL-3994 for acute asthma and other indications, today announced results for its fourth quarter and fiscal year ended June 30, 2011.  

Recent Highlights

  • Palatin initiated enrollment in its Phase 2B trial with bremelanotide in premenopausal women with female sexual dysfunction.
  • Palatin announced commencement of a Phase 1 trial of AZD2820, under development for treatment of obesity, in collaboration with AstraZeneca.
  • In March 2011, Palatin closed on a $23.0 million firm commitment public offering consisting of 23 million units at a price to the public of $1.00.  Net proceeds to Palatin after deducting underwriting discounts and other offering expenses were $21.0 million.

  • Fourth Quarter and Fiscal Year End 2011 ResultsPalatin reported a net loss of $3.3 million, or $(0.09) per basic and diluted share, for the quarter ended June 30, 2011, compared to a net loss of $4.2 million, or $(0.40) per basic and diluted share, for the same period in 2010.The change in net loss for the quarter ended June 30, 2011 compared to the net loss for the quarter ended June 30, 2010 was primarily attributable to $1.3 million of non-cash, non-operating income, which represents the decrease in estimated fair value of the warrant liability from March 31, 2011 through May 11, 2011, the date the warrants ceased to be classified as a liability upon stockholder approval of the increase in authorized common stock

    Palatin's net loss for the year ended June 30, 2011 was $12.8 million, or $(0.64) per basic and diluted share, compared to a net loss of $1.8 million, or $(0.18) per basic and diluted share, for the year ended June 30, 2010.  

    The change in net lo
    '/>"/>

    SOURCE Palatin Technologies, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5

    Related biology technology :

    1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
    2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
    3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
    4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
    5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
    6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
    7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
    8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
    9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
    10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
    11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/30/2015)... , July 30, 2015   Aratana ... pet therapeutics company focused on the licensing, development ... animals, today announced that its strategic partner VetStem ... dose confirmation study of AT-016, an adipose-derived allogeneic ... the treatment of osteoarthritis pain in dogs. ...
    (Date:7/30/2015)... 30, 2015  Discovery Laboratories, Inc. (Nasdaq: ... the second $1.0M tranche under a previously awarded ... valued at up to $3.0 million to support ... as a potential medical countermeasure to mitigate acute ... awarded an initial $1.0 million under this grant ...
    (Date:7/29/2015)... BANGALORE , July 30, 2015 ... Cell Market - Growth, Trends & Forecasts (2015-2020), , published ... worth US$ 30.25 billion by the end of 2020, with ... globally accounting for more than 40% of the global market ... grow at a CAGR of 13.7% during the period of ...
    (Date:7/29/2015)... SAN FRANCISCO , July 29, 2015 /PRNewswire/ ... trialling mobile molecular testing for applications in food ... Ubiquitome,s hand-held, battery powered real-time PCR device, the ... the farm right through to the supermarket shelf ... world. This includes involvement in animal disease control ...
    Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 2Discovery Labs Receives $1.0 million under an SBIR Grant in Continuing Support of the Development of Aerosolized KL4 Surfactant to Address Radiation-Induced Lung Injury 3Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 2Asia Pacific to Dominate the Global Stem Cell Market - Vericel Corporation, Ocata Therpeutics, Athersys Inc., Cryo-Cell International, Geron Corporation, StemCells, Inc. Among the Major Players 3AsureQuality and Ubiquitome Partner on Applications for Mobile Molecular Food Safety Testing 2
    ... Inc., the leading,systems biology tools company, announced today ... MetaMiner Cardiac,Consortium. The goal of the Consortium is ... platform for cardiovascular diseases in the,world. The Consortium ... specific pathway maps and networks built by experts ...
    ... researchers at ... with internal solutions, REDWOOD CITY, Calif., April 15 ... life science researchers, and,Pfizer Pharmaceuticals, Inc. (NYSE: PFE ... a strategic,partnership today. This new multi-year partnership promotes enterprise-wide,deployment ...
    ... Kiadis,Pharma announced today that the U.S. Food ... Rhitol(TM) Orphan Drug Designation for the treatment ... complication of allogeneic,bone marrow transplantation is highly ... patient is unresponsive to steroid treatment.,Rhitol(TM) has ...
    Cached Biology Technology:The Scripps Translational Science Institute Joins The MetaMiner Cardiac Consortium 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 2Ingenuity Systems and Pfizer Announce Strategic Partnership for Pathway Analysis 3Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA 2
    (Date:7/20/2015)... 20, 2015  Acuity Market Intelligence,s latest research ... of Commerce and Privacy" forecasts that between 2014 ... will be downloaded to smart mobile devices by ... market is projected to generate more than $67.9 ... seven-year forecast period.    "Biometrics is ...
    (Date:7/9/2015)... 9, 2015  Unchained Labs just can,t get ... of Avid Nano. Avid Nano designs, develops and ... Also today, Unchained Labs UNcaged ... to use protein sizing system. The pUNk is ... hydrodynamic size, size distribution, aggregation population and molecular ...
    (Date:7/8/2015)... July 8, 2015 The consumer products ... summer,s must have products such as wearables, smart wallets & ... for biometrics based devices continues to rapidly grow.  Biometrics & ... NXTD ), Google Inc. (NASDAQ: GOOG ), Apple ... ), GoPro, Inc. (NASDAQ: GPRO ) and Baidu Inc. ...
    Breaking Biology News(10 mins):Biometrics on Smart Mobile Devices to Redefine Digital Identity with 12.9 Billion Biometric App Downloads between 2014 and 2020 2Unchained Labs just can't get enough, acquires Avid Nano, rocks out the new pUNk! 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 2Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 3Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 4Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 5Consumers Flock to This Summer's Must Have Tech Gadgets as Latest Digital Wallets, Smart Technology & Wearable Products Continue to Grow in Popularity & Functionality 6
    ... How marine animals find their way back to their birthplace ... ocean has mystified scientists for more than a century. But ... Hill think they might finally have unraveled the secret. ... may read the magnetic field of their home area and ...
    ... STANFORD, Calif. Scientists around the world may benefit ... that will help them to home in on the ... Arend Sidow, PhD, associate professor of pathology and of ... launched the novel bioinformatics tool, which enlists evolution as ...
    ... will hold a colloquium to examine what lies ahead ... organisms. Leading researchers and students will discuss new tools ... from the perspectives of ecology, paleontology, phylogenetics, and biodiversity ... the Sackler Colloquium series, the event will take place ...
    Cached Biology News:No place like home: New theory for how salmon, sea turtles find their birthplace 2No place like home: New theory for how salmon, sea turtles find their birthplace 3Powerful online tool for protein analysis provided pro bono by Stanford geneticist 2Powerful online tool for protein analysis provided pro bono by Stanford geneticist 3
    ... I from E. coli is ... enzyme also contains both 5'--3'and ... exonuclease activity enables the enzyme ... in the DNA as starting ...
    Request Info...
    ... of the human Topoisomerase II gene. ... state of nucleic acids by passing an intact ... a separate DNA helix (1,2) . As a ... enzyme can relax negatively or positively supercoiled DNA, ...
    ... Exonuclease-free Klenow Fragment is a genetically engineered Klenow ... activity has been removed, leaving only the 5 ... activity makes Exo- Klenow Fragment the enzyme of ... probes by the random primed method, and for ...
    Biology Products: